38841-54-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2,6-Dichloro-4-methylnicotinamide is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with improved therapeutic properties.
Used in Research and Development:
As a nicotinamide analog, 2,6-Dichloro-4-methylnicotinamide is used in research and development for studying its potential biological activities and exploring its applications in medicine and pharmacology. Researchers can use 2,6-DICHLORO-4-METHYLNICOTINAMIDE to investigate its interactions with biological targets and evaluate its efficacy in treating various diseases.
Used in Medicinal Chemistry:
2,6-Dichloro-4-methylnicotinamide is employed in medicinal chemistry for the design and optimization of novel therapeutic agents. Its structural similarities to nicotinamide enable chemists to modify its properties and develop new compounds with enhanced pharmacological profiles.
Used in Drug Discovery:
2,6-Dichloro-4-methylnicotinamide is utilized in drug discovery processes to identify potential lead compounds with therapeutic potential. Its unique chemical features make it a valuable tool for screening and evaluating new drug candidates in various disease models.

InChI:InChI=1/C7H6Cl2N2O/c1-3-2-4(8)11-6(9)5(3)7(10)12/h2H,1H3,(H2,10,12)

Upstream product

• 875-35-4 2,6-dichloro-4-methylnicotinonitrile 
• 56950-89-1 2,6-dichloro-4-methylnicotinoyl chloride 
• 5444-02-0 2,6-dihydroxy-3-cyano-4-methylpyrimidine 
• 62774-90-7 2,6-dichloro-4-methyl-nicotinic acid 
• 5444-02-0 3-cyano-4-methyl-6-hydroxypyrid-2-one 

Downstream Products

• 62774-90-7 2,6-dichloro-4-methyl-nicotinic acid 
• 1612761-97-3 benzenesulfonic acid 6-(3,5-dimethylpyrazol-1-yl)-4-methyl-1H-pyrazolo[3,4-b]pyridine-3-yl ester 
• 1612761-98-4 toluene-4-sulfonic acid 6-(3,5-dimethylpyrazol-1-yl)-4-methyl-1H-pyrazolo[3,4-b]pyridine-3-yl ester 
• 1612761-99-5 benzoic acid 1-benzoyl-6-(3,5-dimethylpyrazol-1-yl)-4-methyl-1H-pyrazolo[3,4-b]pyridine-3-yl ester 
• 129432-25-3 2,6-dichloro-3-amino-4-methylpyridine 

Relevant academic research and scientific papers

Synthesis and structure of novel 6-(pyrazol-1-yl)-4-methyl-1H-pyrazolo[3,4- b]pyridin-3-ol derivatives

New 6-(pyrazol-1-yl)pyrazolo[3,4-b]pyridin-3-ol compounds were synthesized by cyclization reaction from 2,6-dichloro-4-methylnicotinonitrile. Their derivatives exist as the 3-hydroxy tautomer. The structure of the compound 1a of one of the resulting compounds was studied in detail by X-ray diffraction.

Method for preparing amide compounds by using supported metal oxide catalytic material

The invention relates to a catalyst for preparing amide compounds, and aims to provide a method for preparing amide compounds by using a supported metal oxide catalytic material. The method comprisesthe following steps: uniformly mixing a solvent, water, an organic nitrile compound and the catalytic material; performing a reaction at 50-180 DEG C for 0.5-48 h; and hydrating and converting the organic nitrile compound into the corresponding amide compounds through the catalytic hydration effect of the catalyst in the reaction process. Adsorption and activation of the catalytic material to water molecules can be effectively regulated by regulating metal components loaded on the catalytic material and a catalytic material carrier, so that important amide compounds in chemical and agricultural processes are efficiently prepared. The provided method for preparing the amide compounds is effect, and has the advantages of high atom utilization rate in the reaction process, low reaction temperature, no additional reaction assistant in the synthesis process, no generation of toxic or harmful byproducts after the reaction, and green and environment-friendly synthesis process.

OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Preparation method for nevirapine intermediate

The invention provides a preparation method for a nevirapine intermediate. The preparation method comprises: performing a cyclization reaction of ammonia water, methyl cyanoacetate and methyl acetoacetate to form a compound hydroxyl: 2,6-dihydroxy-3-cyano-4-methylpyridine; adding triethylamine dropwise, introducing chlorine gas at the temperature until the reaction is complete, and obtaining 2,6-dichloro-3-cyano-4-methylpyridine; adding concentrated sulfuric acid, heating to 120 DEG C to react for 3-5 h, and then cooling to 60 DEG C; adding water to perform hydrolysis reaction, and obtaining 2,6-dichloro-3-amido-4-methylpyridine; adding a degradation reagent sodium hypochlorite, and obtaining a nevirapine intermediate 2,6-dichloro-3-amino-4- methylpyridine by Hofmann reaction. According tothe preparation method, commonly used phosphorus oxychloride is replaced with the directly introduced chlorine gas, which solves the problems that the wastewater content is too high, it is difficultto perform treatment and the odor of phosphorus oxychloride is bad, and the one-time yield of the product is 90.1%.

OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Synthesis, x-ray crystal structure, and computational study of novel pyrazolo[3,4-B]pyridin-3-Ol derivatives

6-(Pyrazol-1-yl)pyrazolo[3 4-b]pyridin-3-ol (3a) was synthesized by cyclization reaction from 2,6-dichloro-4-methylnicotinonitrile. The related sulfonyl and acylated product (4-7) were obtained from the compound 3a and different sulfonyl and acyl chloride

Synthesis of some halogen- and nitro-substituted nicotinic acids and their fragmentation under electron impact

Features of electrophilic and nucleophilic substitution under chlorination and nitration reactions conditions have been investigated for 6-hydroxy- and 6-methyl-substituted derivatives of 3-cyano-4-methyl-2(1H)-pyridones. The polychloro- and nitro-substituted 3-cyano-4-methylpyridines obtained were used as synthons in the synthesis of some polyhalo- and nitro-substituted nicotinic acids and their amides. The fragmentation pathways of the synthesized compounds under electron impact have been studied.

Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes

The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT). An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2- substituted dipyridodiazepinones presented below shows that combined activity against the wild-type and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11- cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 2- substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.

Method for preparing 3-amino-2-chloro-4-alkylpyridines

A process for the preparation of a 3-amino-2-chloro-4-alkylpyridine of the formula: STR1 wherein R is alkyl of from one to three carbon atoms, an intermediate in the preparation of certain 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine compounds useful in the prevention and treatment of HIV infection.